Melanoma treatment obtains funding

Jared Lynch

Updated Feb 3, 2014 – 5.01pm, first published at Jan 30, 2014 – 3.37pm

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Cancer drug developer Viralytics has secured $27 million from a dozen institutional investors.

The funding will allow the Sydney-based company to complete phase two trials of its drug Cavatak, which targets late-stage melanoma.

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Introducing your Newsfeed

Follow the topics, people and companies that matter to you.

Fetching latest articles